Tech Times on MSN
Bayer's Asundexian cuts recurrent stroke risk by 26% without added bleeding, wins China approval as FDA review advances
Bayer's asundexian reduces recurrent stroke risk 26% without added bleeding in OCEANIC-STROKE. Approved in China (Sunharbo®); ...
The authorization to launch Sunharbo in China is the first approval worldwide for a new class of blood-thinning medicines.
Bayer Pharmaceuticals' COO Sebastian Guth discusses how important the use of AI is to the various aspects of the business. He ...
During the first eight CIIE editions, Bayer unveiled 69 debut exhibits, hosted 139 online and offline events, signed 50 cooperation agreements, and secured regulatory launch for 17 so-called ‘CIIE ...
Bayer AG won approval for its stroke prevention drug in China, bolstering the pipeline of the German company’s pharmaceutical ...
Bayer Crop Science at the 9th CIIE [Photo provided to chinadaily.com.cn] Eight China debuts and six CIIE debuts: advancing ...
(Yicai) Oct. 26 -- China stands as one of Bayer's most vital strategic pillars from both an innovation and market perspective ...
Orion's collaboration partner Bayer has submitted an application to the Center of Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the oral androgen receptor ...
Alex Liu discusses the opportunities and challenges for pharma innovators in China and how he led his team to a record patent win China isn’t the easiest jurisdiction to navigate for foreign ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results